Combination drug therapy for lung cancer with brain spread
Treatments studied
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs, sacituzumab govitecan and bevacizumab, for people with a specific type of lung cancer (non-squamous) that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have metastatic non-squamous non-small cell lung cancer that has spread to your brain.
- You have at least one untreated brain tumor that is 5 mm or larger and not in a sensitive area of the brain.
- You have previously tried immunotherapy, chemotherapy, or targeted therapy and it stopped working.
- You are generally in good health (able to do daily activities without much help) with a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, sacituzumab tirumotecan and bevacizumab, for people with EGFR-mutant lung cancer that has spread to the brain. It aims to see if this combination can shrink tumors and improve outcomes after standard EGFR inhibitor treatment has stopped working.
This trial tests a combination of a targeted drug called sacituzumab govitecan (Trodelvy) with radiation to the head for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this combination can shrink brain tumors and improve outcomes.
This trial tests a combination of two drugs — a targeted chemotherapy and an immunotherapy — given before surgery for people with early-stage but locally advanced lung cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of two drugs, Sacituzumab Govitecan and Bevacizumab, for people with advanced triple-negative breast cancer that has already been treated. The goal is to see if the combination works better than standard treatments.
This clinical trial tests a combination of two drugs—Sac-TMT (an antibody-drug conjugate that targets tumor cells) and bevacizumab (a drug that blocks blood vessel growth to tumors)—as a second-line treatment for advanced non-squamous non-small cell lung cancer. The goal is to see if this combination can help people whose cancer has progressed after initial chemotherapy and immunotherapy.
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.